Status In progress
Process STA 2018
ID number 916

Provisional Schedule

Final appraisal document 28 November 2019 - 12 December 2019
Expected publication 15 January 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Pfizer
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Care
  Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Breast Cancer Group

Commentators

Comparator companies Eli Lilly
  Novartis
  Roche Products
General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health, Social Services and Public Safety - Northern Ireland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
10 October 2019 Committee meeting: 1
08 February 2019 Invitation to participate
31 December 2018 - 23 January 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
30 November 2018 In progress, Following publication of TA495 this appraisal will now restart. The timelines for this appraisal have been set in order that key overall survival data can be included in the company’s submission. The first committee meeting will take place in October 2019.
03 February 2017 Suspended, Pfizer has indicated that they will not be making a submission to NICE for the above indication until the outcome of the palboclicib plus an aromatase inhibitor appraisal [ID915] is final. In the meantime appraisal [ID916] will be suspended while NICE considers the options for rescheduling.
23 November 2016 The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has now been rescheduled. The first committee meeting will take place in June 2017.
20 October 2016 The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has been suspended at the request of Pfizer. The Company submission of a value proposition for palbociclib after endocrine therapy will follow after the outcome of the appraisal of palbociclib for previously untreated disease [ID915] is known.
06 October 2016 Invitation to participate
13 May 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance